Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers


Plots, Aggression, Duplicity...and Homeland Defense

Why go it alone with a Bush-started war on Iraq that virtually the whole world condemns ("The cost of fighting terrorism," "9.11: What has changed," Special Report, Sept. 16)? Because George W.'s Administration wants Iraq. Iran, Arabia, Syria, Jordan, Kuwait, and Turkey are all next door. It's 300 miles to Israel and Palestine, 500 to Cairo, and a strategic gateway to Africa, where the U.S. has no presence. There's direct land access to the Persian Gulf--and a dream of U.S. domination of the Middle East, with lots more cheap oil, all in the name of countering or containing potential terrorism.

Leonard Zane

Sierra Madre, Calif.

Let's see...bomb-sniffing dogs are several times more accurate than bomb-detecting machines and several times faster to deploy ("High tech is starting to kick in," Special Report, Sept. 16). Why would our government spend billions of dollars for fallible machines over cheap, reliable dogs? Oh, of course--dog trainers don't hire million-dollar lobbyists and don't make multimillion-dollar campaign contributions.

Chris Cauble

Helena, Mont.

There aren't enough dollars if you think security is something that can be bought ("Real security won't come easy--or cheap," Editorials, Sept. 16). Taking a clue from software engineering, you can see that security hinges on simplicity and well-defined communications. That's one good reason why Microsoft Corp. will have to start over from scratch if they want to produce secure systems [instead of] never-ending security patches. On a societal level, many of the fixes actually cause the problem--repressive government triggers opposition; reduction of freedom breeds resistance.

Rogier van Vlissingen

Riverdale, N.Y. It's a good thing that MBA programs are no longer giving short shrift to ethics and responsibility ("For MBAs, soul-searching 101," Management, Sept. 16). But will it do any good? Business schools also ramped up ethics after the Wall Street scandals in the 1980s, and we can see how successful they have been at getting the message across.

Our research on MBA students and programs makes it clear that for teaching on ethical dilemmas and the wider responsibilities of business to stick, the content needs to gravitate from the ethics classroom into the courses that matter in the MBA hierarchy--strategy, risk management, finance, accounting. Ethics courses are at best marginalized and at worst resented.

The recruitment market continues to reward "hard" skills at the expense of the real-life skills and values clarification that are at the base of ethical decision-making. MBA students expect to have to compromise their values in the workplace. They may know the difference between right and wrong, but are they equipped with the strategies and skills to [enact changes in the system] without putting their jobs on the line?

Judith F. Samuelson

Aspen Institute

New York

Editor's note: The writer is executive director of the Initiative for Social Innovation through Business. Gary S. Becker does not seem to realize that an ineffective drug is dangerous, because it allows the disease to progress and prevents the use of another drug that could have been effective ("Get the FDA out of the way, and drug prices will drop," Economic Viewpoint, Sept. 16). In pharmaceutical research, there is a constant, but necessary, antagonism between scientists and managers. The ever-looming threat of Food & Drug Administration action often tips the scale in favor of the scientists. Relax the FDA insistence on efficacy, and the managers will win. But managers do not discover new drugs; scientists do. Scientists in pharmaceutical houses, in the FDA, and in medicine all support the need for efficacy.

Donald A. Windsor

Norwich, N.Y.

Editor's note: The writer has spent three decades in pharmaceutical R&D. The only thing worse than not having insurance is thinking you do when you really don't ("Dogs and teen drivers could leave you broke," BusinessWeek Investor, Sept. 16). The only time I tried using my umbrella policy, my consistently top-rated company, which had all of my insurance business for 38 years, refused coverage because the suing person "alleged" that I caused intentional harm. Intentional harm is not covered, it seems, even if only alleged.

Harry E. Rodman Jr.

Pownal, Vt.

blog comments powered by Disqus